查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1922939

可溶解微針貼片市場：依聚合物類型、應用、最終用戶和通路分類－2026-2032年全球預測

Dissolvable Microneedle Patches Market by Polymer Type, Application, End User, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 193 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，可溶解微針貼片市場價值將達到 5.3456 億美元，到 2026 年將成長至 6.2979 億美元，到 2032 年將達到 17.8913 億美元，複合年成長率為 18.83%。

關鍵市場統計數據
基準年 2025 5.3456億美元
預計年份：2026年 6.2979億美元
預測年份 2032 17.8913億美元
複合年成長率 (%) 18.83%

對可溶解微針貼片的科學進步和醫療保健需求進行了簡潔的策略概述，推動了其在臨床和消費市場的應用。

可溶解微針貼片融合了材料科學、藥物遞送創新和以患者為中心的醫療保健設計，有望重新定義經皮給藥方式。這些裝置可在表皮內溶解，遞送活性成分，且不會產生銳器廢棄物，並可實現無痛、微創給藥，符合現代醫療對安全性、依從性和便捷性的追求。聚合物化學、精密微加工和無菌生產技術的進步正在融合，以降低技術壁壘，並將臨床應用從治療領域擴展到美容領域。

材料創新、監管政策的明確性以及以患者為中心的給藥模式如何改變可溶解微針貼片的研發路徑和商業性機會？

隨著技術的成熟、監管政策的明朗化以及新興應用案例的湧現，可溶解微針貼片的市場格局正在迅速變化，商業化路徑也隨之重塑。材料創新使得產品從一次性試點原型過渡到適用於嚴格無菌生產的可重複配方。與科技進步同步，醫療服務模式也正在改變。便利的施用器和清晰的說明書讓非專業使用者也能輕鬆上手，居家給藥和診所內自我護理正變得越來越可行。這些趨勢正在減少傳統腸外給藥療法帶來的阻力，為過去因害怕針頭和就醫障礙而受困的患者群體開闢新的途徑。

美國不斷變化的關稅政策對製造商的營運和策略影響迫使他們重新思考微針產品的採購、在地化和供應鏈韌性。

目前及預期中的關稅政策對從事可溶解微針貼片生產和分銷的企業具有獨特的營運和策略影響。聚合物、精密模具和成品貼片的進口關稅提高，增加了依賴全球供應鏈的製造商的到岸成本，促使採購部門重新評估供應商合約和庫存策略。為此，一些製造商正在加快關鍵原料的在地採購，實現供應商多元化，並將關稅風險納入總成本模型，以維持利潤率和專案進度。

細分市場分析揭示了應用、聚合物選擇、終端用戶需求和通路如何共同影響產品設計、監管要求和商業化路徑。

可溶解微針貼片的細分分析突顯了不同應用、聚合物選擇、終端用戶和分銷管道所帶來的不同應用路徑和技術優先順序。依應用分類，市場可分為化妝品及藥品兩大應用領域，而藥品開發可進一步細分為止痛藥製劑、胰島素輸送系統及候選疫苗。每個治療領域都提出了獨特的性能、穩定性和監管要求，這些要求會影響製劑策略和臨床試驗設計。

美洲、歐洲、中東和非洲以及亞太地區的區域法規結構、製造業生態系統和商業性動態將如何以獨特的方式影響技術採納路徑和供應策略

區域趨勢將對可溶解微針貼片的推廣應用時間表、監管要求和製造地產生顯著影響。在美洲，監管機構和醫療支付方對能夠提高患者依從性並減輕臨床負擔的技術的接受度不斷提高，為門診和居家醫療的試驗計畫創造了有利環境。尤其是在美國，政府正加大對國內生產能力的投資，並積極進行公私合營舉措，以支持疫苗和生物製藥遞送技術的創新。

提供競爭洞察，將製藥贊助商、醫療設備專家、材料技術創新者和契約製造製造商聯繫起來，以加速商業化和規模化生產。

溶解性微針貼片領域的競爭動態由成熟的製藥公司、專業的器材開發商、材料供應商以及專注於平台技術的敏捷型新創公司共同塑造。領先的製藥公司利用其監管經驗和臨床Start-Ups基礎設施來推進候選療法的研發，而器械專家則提供微加工技術和組裝規模化生產能力。材料公司和聚合物創新者在上游工程，他們提供針對溶解速率、機械強度和生物相容性最佳化的材料等級和配方。

明確且優先的行動方案，協調經營團隊在配方設計、監管規劃、供應鏈韌性、臨床證據、夥伴關係和永續性的工作，以加速產品推廣和規模化應用。

行業領導者應優先考慮技術選擇、監管策略和商業性執行的整合方法，以抓住短期機會並建立長期韌性。首先，應投資於聚合物選擇和配方開發，以平衡機械性能、生物相容性和可擴展的生產流程，從而減少下游技術轉移的阻力。其次，應儘早制定監管藍圖，以解決組合產品分類、無菌檢驗和人體工學測試等問題，從而與監管機構和支付方進行高效溝通。

一種透明且可重複的調查方法，結合了相關人員訪談、技術文獻、監管分析、專利研究和供應鏈檢驗，以支援策略決策。

本研究整合了一手和二手資料，得出嚴謹且可用於決策的分析結果。一手資料包括對藥物研發、醫療設備設計、材料供應、臨床實踐和契約製造等領域的相關人員進行結構化訪談，以及與監管事務專家和採購主管進行討論，以獲得關於生產限制、監管預期、臨床終點和商業化準備情況的第一手資訊。

簡明扼要的結論整合了技術可行性、監管要求和策略重點，有助於指導相關人員實現永續的採用和商業化。

溶解性微針貼片正處於一個策略轉折點，科學進步、監管力度和不斷變化的護理模式在此交匯，為治療和美容應用開闢了一條商業性化的道路。該技術的優勢——減輕手術疼痛、消除銳器廢棄物以及可自行使用——滿足了特定的臨床和消費者需求，而聚合物科學和製造技術的進步正在降低可靠的大規模生產的門檻。

目錄

第1章：序言

第2章調查方法

  • 研究設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查前提
  • 調查限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會地圖
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

8. 依聚合物類型分類的可溶解微針貼片市場

  • 幾丁聚醣
  • 玻尿酸
  • 聚乳酸
  • 聚乙烯吡咯烷酮

9. 按應用分類的可溶解微針貼片市場

  • 化妝品
  • 製藥
    • 止痛藥
    • 胰島素
    • 疫苗

第10章 依終端用戶分類的可溶解微針貼片市場

  • 診所
  • 家庭醫療保健
  • 醫院
  • 研究所

第11章 依通路分類的可溶解微針貼片市場

  • 醫院藥房
  • 網路藥房
  • 零售藥房

第12章 各地區可溶解微針貼片市場

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第13章 按組別分類的可溶解微針貼片市場

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章 各國可溶解微針貼片市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

15. 美國可溶解微針貼片市場

第16章 中國可溶微針貼片市場

第17章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • 111Skin
  • 3M Company
  • AdminMed, Inc.
  • AND SHINE
  • Beijing CAS Microneedle Technology
  • Corium, Inc.
  • CosMED Pharmaceutical Co., Ltd.
  • ESK GmbH
  • Hero Cosmetics
  • Kindeva Drug Delivery
  • LTS Lohmann Therapie-Systeme AG
  • Micron Biomedical Inc.
  • Microneedle Biosystems NV
  • Micropoint Technologies
  • NanoPass Technology Ltd.
  • Nissha Co., Ltd.
  • Rani Therapeutics LLC
  • Raphas Co., Ltd.
  • Shiseido Company, Limited
  • Skyn Iceland
  • Vaxess Technologies, Inc.
  • Zhuhai Youwe Biotechnology
  • Zosano Pharma Corp.
Product Code: MRR-867BED9A9E6D

The Dissolvable Microneedle Patches Market was valued at USD 534.56 million in 2025 and is projected to grow to USD 629.79 million in 2026, with a CAGR of 18.83%, reaching USD 1,789.13 million by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 534.56 million
Estimated Year [2026] USD 629.79 million
Forecast Year [2032] USD 1,789.13 million
CAGR (%) 18.83%

A succinct strategic introduction summarizing the scientific advances and healthcare imperatives driving dissolvable microneedle patches toward broader clinical and consumer adoption

Dissolvable microneedle patches represent a convergence of materials science, drug delivery innovation, and patient-centric healthcare design, poised to redefine transdermal administration. These devices dissolve in the epidermis to deliver active compounds without generating sharps waste, enabling painless, minimally invasive dosing that aligns with modern priorities for safety, adherence, and convenience. Advances in polymer chemistry, precision microfabrication, and sterile manufacturing have collectively reduced technical barriers, while increasing clinical exploration across therapeutic and cosmetic domains.

As interest grows from pharmaceutical developers, cosmetic formulators, and contract manufacturers, the ecosystem has shifted from proof-of-concept research toward scalable production and regulatory engagement. Clinical programs have expanded beyond topical analgesia to include systemic biologics such as insulin and vaccine candidates, reflecting the technology's versatility. Concurrently, regulatory bodies have issued guidance and established frameworks that emphasize quality-by-design, biocompatibility testing, and robust sterility assurance. Taken together, these dynamics create a near-term imperative for leaders to align R&D pipelines, supply chain strategies, and health-economic narratives to capture uptake as adoption moves from niche trials to routine clinical and consumer use.

How materials breakthroughs, regulatory clarity, and patient-centric delivery models are transforming development pathways and commercial opportunities for dissolvable microneedle patches

The landscape for dissolvable microneedle patches is changing rapidly as technology maturation, regulatory clarity, and new use cases converge to reshape commercialization pathways. Materials innovation has enabled a shift from single-use exploratory prototypes to reproducible formulations suitable for stringent sterile production. This technical progression is matched by a shift in care delivery models: home administration and clinic-based self-care are increasingly viable, supported by user-friendly applicators and clear instructions for non-specialist users. These trends reduce the friction traditionally associated with parenteral therapies and open channels to patient populations that previously struggled with needle aversion or access barriers.

Parallel to technical and delivery changes, the regulatory environment is responding with clearer expectations for device-drug combinations, sterility controls, and biocompatibility. Payors and procurement bodies are beginning to evaluate value propositions that emphasize adherence, reduced clinic visits, and lower sharps waste disposal costs. Strategic partnerships between pharmaceutical sponsors, device specialists, and contract manufacturers are accelerating, enabling scale-up and multi-site distribution. As a result, incumbent assumptions about formulation limits and clinical applicability are being overturned, creating a landscape in which novel therapeutic and preventive applications can be commercialized more rapidly than a few years ago.

Operational and strategic consequences of evolving United States tariff policy that compel manufacturers to rethink sourcing, localization, and supply chain resilience for microneedle products

Current and prospective tariff policies introduce a distinct set of operational and strategic effects for organizations involved in the production and distribution of dissolvable microneedle patches. Increased import duties on polymers, precision tooling, and finished patches can raise landed costs for manufacturers that rely on global supply chains, prompting procurement teams to reevaluate supplier contracts and inventory strategies. In response, some manufacturers are accelerating localization of critical inputs, diversifying supplier bases, and incorporating tariff risk into total cost models to preserve margin and program timelines.

Beyond direct cost implications, tariff regimes influence sourcing decisions for specialized polymers and device components, shifting investment toward vertically integrated production or near-shore partnerships that reduce exposure to cross-border duties. Regulatory compliance and customs classification become operational priorities, as misclassification can trigger retroactive liabilities. To mitigate disruption, firms are investing in scenario planning, tariff engineering exercises, and collaborative engagements with trade consultants. These adaptive measures are altering capital allocation and go-to-market sequencing, encouraging a careful balance between cost optimization and maintaining the agility needed for clinical supply and commercial launches.

Segment-driven insights revealing how applications, polymer choices, end-user requirements, and distribution channels collectively shape product design, regulatory needs, and commercialization pathways

Segmentation insights for dissolvable microneedle patches highlight differentiated adoption paths and technical priorities across application, polymer selection, end user, and distribution channel. When viewed by application, the market is divided between cosmetic use cases and pharmaceutical indications, with pharmaceutical development further segmented into analgesic formulations, insulin delivery systems, and vaccine candidates; each therapeutic area imposes distinct performance, stability, and regulatory requirements that influence formulation strategies and clinical trial design.

Polymer choice is a core technical determinant, with chitosan offering biodegradability and mucoadhesive properties, hyaluronic acid providing hydrating and dermal compatibility advantages, polylactic acid contributing mechanical strength and controlled dissolution characteristics, and polyvinylpyrrolidone supplying solubility and ease of processing. End-user contexts shape usability and packaging requirements: clinics and hospitals demand batch traceability and compatibility with sterile workflows, home healthcare environments prioritize ease of self-administration and patient instructions, and research laboratories focus on formulation flexibility and rapid iteration. Distribution pathways create additional constraints and opportunities, where hospital pharmacies require predictable cold chain or controlled storage practices, online pharmacies emphasize clear labeling and logistics for direct-to-consumer delivery, and retail pharmacies must accommodate point-of-sale counseling and in-store inventory management. Collectively, these segments inform product design, regulatory strategy, and commercial prioritization, guiding where clinical evidence and supply investments will most rapidly translate into adoption.

How regional regulatory frameworks, manufacturing ecosystems, and commercial dynamics in the Americas, Europe Middle East & Africa, and Asia-Pacific uniquely influence adoption pathways and supply strategies

Regional dynamics exert a pronounced influence on adoption timelines, regulatory requirements, and manufacturing footprints for dissolvable microneedle patches. In the Americas, regulatory agencies and healthcare payors are increasingly receptive to technologies that improve adherence and reduce clinical burden, producing an environment favorable to pilot programs in outpatient clinics and home healthcare. The United States in particular shows growing investment in domestic manufacturing capacity and public-private initiatives that support vaccine and biologic delivery innovations.

In Europe, Middle East & Africa, fragmented regulatory pathways and diverse reimbursement environments create both challenges and localized opportunities, as national health systems prioritize cost-effective interventions and sustainability. Regulatory harmonization efforts and multi-country clinical programs can accelerate broader uptake, but companies must tailor dossiers and distribution strategies to country-specific requirements. In the Asia-Pacific region, a combination of large patient populations, strong contract manufacturing ecosystems, and proactive regulatory authorities has led to rapid scaling of clinical research and manufacturing partnerships. Regional supply chain strategies increasingly favor geographically distributed production to reduce lead times and respond to local demand fluctuations, while commercial approaches emphasize partnerships with local distributors, pharmacy chains, and digital health platforms to reach diverse end users.

Insight into the competitive ecosystem where pharmaceutical sponsors, device specialists, materials innovators, and contract manufacturers converge to accelerate commercialization and scale

Competitive dynamics in the dissolvable microneedle patch space are shaped by a blend of established pharmaceutical manufacturers, specialized device developers, materials suppliers, and nimble startups focusing on platform technologies. Leading pharmaceutical firms are leveraging regulatory experience and clinical trial infrastructure to advance therapeutic candidates, while device specialists contribute microfabrication expertise and assembly scale-up capabilities. Materials companies and polymer innovators play a critical upstream role by delivering grades and formulations optimized for dissolution kinetics, mechanical strength, and biocompatibility.

Startups and academic spinouts often lead on early-stage clinical proof-of-concept and novel applicator designs, creating attractive licensing or partnership opportunities for larger organizations seeking accelerated entry. Contract development and manufacturing organizations are emerging as pivotal partners for scale-up, offering sterile fill-finish, precision micromolding, and quality management systems that meet combination product expectations. Intellectual property, regulatory filings, and a growing base of clinical evidence are increasingly the differentiators that determine which firms move from pilot programs to commercial launches. Strategic alliances, co-development agreements, and selective M&A activity are expected to continue as companies align complementary capabilities across materials, device engineering, and clinical access.

Clear, prioritized actions for executives to align formulation, regulatory planning, supply resilience, clinical evidence, partnerships, and sustainability to accelerate adoption and scale

Industry leaders should prioritize an integrated approach that aligns technology choices, regulatory strategy, and commercial execution to capture near-term opportunities while building long-term resilience. First, invest in polymer selection and formulation development that balance mechanical performance with biocompatibility and scalable manufacturing processes to reduce downstream tech transfer friction. Second, develop a regulatory roadmap early that addresses combination product classification, sterility validations, and human factors testing, enabling more efficient interactions with regulators and payors.

Third, build supply chain redundancy through qualified alternate suppliers and regional manufacturing partnerships to mitigate tariff exposure and logistical disruption. Fourth, create clinical development programs that generate compelling evidence for adherence, safety, and comparative effectiveness in target end-user settings such as clinics, hospitals, and home healthcare environments. Fifth, pursue strategic collaborations with contract manufacturers to accelerate sterile scale-up and with digital health providers to support patient education and adherence monitoring. Finally, embed sustainability and waste-reduction narratives into product positioning to resonate with procurement and health-system stakeholders, while ensuring commercial materials and packaging meet retail and online distribution requirements.

A transparent and reproducible research methodology combining stakeholder interviews, technical literature, regulatory analysis, patent review, and supply chain validation to support strategic decisions

This research synthesizes primary and secondary evidence to produce a rigorous, decision-ready analysis. Primary research included structured interviews with stakeholders across pharmaceutical development, device engineering, materials supply, clinical practice, and contract manufacturing, along with consultations with regulatory affairs specialists and procurement leaders. These engagements provided firsthand perspectives on manufacturing constraints, regulatory expectations, clinical endpoints of interest, and commercial readiness.

Secondary research leveraged peer-reviewed literature, patent filings, clinical trial registries, and public regulatory guidance to map technological capabilities, intellectual property trends, and the evolving evidence base. Technical validation included cross-referencing polymer performance data with materials characterization reports and reviewing sterility and stability protocols used in combination product submissions. Supply chain mapping and tariff impact analysis were informed by trade data, customs classifications, and input from logistics experts. Findings were triangulated across sources and reviewed by subject matter experts to ensure coherence, robustness, and practical relevance to product development and commercialization decisions.

A concise conclusion that synthesizes technological promise, regulatory imperatives, and strategic priorities to guide stakeholders toward sustainable adoption and commercialization

Dissolvable microneedle patches occupy a strategic inflection point where scientific progress, regulatory momentum, and shifting care models converge to create commercially viable pathways for both therapeutic and cosmetic applications. The technology's strengths-including reduced procedural pain, elimination of sharps waste, and potential for self-administration-address concrete clinical and consumer needs, while polymer science and manufacturing improvements are lowering the barriers to reliable production at scale.

Realizing the potential of these platforms requires coordinated attention to formulation optimization, regulatory engagement, robust clinical evidence generation, and resilient supply chains that account for trade policy dynamics. Firms that integrate these elements with targeted commercial strategies-tailored by application, polymer choice, end-user setting, and distribution channel-will be best positioned to convert scientific promise into sustained adoption. Strategic partnerships, careful IP management, and proactive tariff and logistics planning will further distinguish leaders as the technology moves beyond early trials into broader clinical and consumer use.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Dissolvable Microneedle Patches Market, by Polymer Type

  • 8.1. Chitosan
  • 8.2. Hyaluronic Acid
  • 8.3. Polylactic Acid
  • 8.4. Polyvinylpyrrolidone

9. Dissolvable Microneedle Patches Market, by Application

  • 9.1. Cosmetic
  • 9.2. Pharmaceutical
    • 9.2.1. Analgesic
    • 9.2.2. Insulin
    • 9.2.3. Vaccine

10. Dissolvable Microneedle Patches Market, by End User

  • 10.1. Clinics
  • 10.2. Home Healthcare
  • 10.3. Hospitals
  • 10.4. Research Laboratories

11. Dissolvable Microneedle Patches Market, by Distribution Channel

  • 11.1. Hospital Pharmacies
  • 11.2. Online Pharmacies
  • 11.3. Retail Pharmacies

12. Dissolvable Microneedle Patches Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Dissolvable Microneedle Patches Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Dissolvable Microneedle Patches Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Dissolvable Microneedle Patches Market

16. China Dissolvable Microneedle Patches Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. 111Skin
  • 17.6. 3M Company
  • 17.7. AdminMed, Inc.
  • 17.8. AND SHINE
  • 17.9. Beijing CAS Microneedle Technology
  • 17.10. Corium, Inc.
  • 17.11. CosMED Pharmaceutical Co., Ltd.
  • 17.12. ESK GmbH
  • 17.13. Hero Cosmetics
  • 17.14. Kindeva Drug Delivery
  • 17.15. LTS Lohmann Therapie-Systeme AG
  • 17.16. Micron Biomedical Inc.
  • 17.17. Microneedle Biosystems NV
  • 17.18. Micropoint Technologies
  • 17.19. NanoPass Technology Ltd.
  • 17.20. Nissha Co., Ltd.
  • 17.21. Rani Therapeutics LLC
  • 17.22. Raphas Co., Ltd.
  • 17.23. Shiseido Company, Limited
  • 17.24. Skyn Iceland
  • 17.25. Vaxess Technologies, Inc.
  • 17.26. Zhuhai Youwe Biotechnology
  • 17.27. Zosano Pharma Corp.

LIST OF FIGURES

  • FIGURE 1. GLOBAL DISSOLVABLE MICRONEEDLE PATCHES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL DISSOLVABLE MICRONEEDLE PATCHES MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL DISSOLVABLE MICRONEEDLE PATCHES MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL DISSOLVABLE MICRONEEDLE PATCHES MARKET SIZE, BY POLYMER TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL DISSOLVABLE MICRONEEDLE PATCHES MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL DISSOLVABLE MICRONEEDLE PATCHES MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL DISSOLVABLE MICRONEEDLE PATCHES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL DISSOLVABLE MICRONEEDLE PATCHES MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL DISSOLVABLE MICRONEEDLE PATCHES MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL DISSOLVABLE MICRONEEDLE PATCHES MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES DISSOLVABLE MICRONEEDLE PATCHES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA DISSOLVABLE MICRONEEDLE PATCHES MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL DISSOLVABLE MICRONEEDLE PATCHES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL DISSOLVABLE MICRONEEDLE PATCHES MARKET SIZE, BY POLYMER TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL DISSOLVABLE MICRONEEDLE PATCHES MARKET SIZE, BY CHITOSAN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL DISSOLVABLE MICRONEEDLE PATCHES MARKET SIZE, BY CHITOSAN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL DISSOLVABLE MICRONEEDLE PATCHES MARKET SIZE, BY CHITOSAN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL DISSOLVABLE MICRONEEDLE PATCHES MARKET SIZE, BY HYALURONIC ACID, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL DISSOLVABLE MICRONEEDLE PATCHES MARKET SIZE, BY HYALURONIC ACID, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL DISSOLVABLE MICRONEEDLE PATCHES MARKET SIZE, BY HYALURONIC ACID, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL DISSOLVABLE MICRONEEDLE PATCHES MARKET SIZE, BY POLYLACTIC ACID, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL DISSOLVABLE MICRONEEDLE PATCHES MARKET SIZE, BY POLYLACTIC ACID, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL DISSOLVABLE MICRONEEDLE PATCHES MARKET SIZE, BY POLYLACTIC ACID, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL DISSOLVABLE MICRONEEDLE PATCHES MARKET SIZE, BY POLYVINYLPYRROLIDONE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL DISSOLVABLE MICRONEEDLE PATCHES MARKET SIZE, BY POLYVINYLPYRROLIDONE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL DISSOLVABLE MICRONEEDLE PATCHES MARKET SIZE, BY POLYVINYLPYRROLIDONE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL DISSOLVABLE MICRONEEDLE PATCHES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL DISSOLVABLE MICRONEEDLE PATCHES MARKET SIZE, BY COSMETIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL DISSOLVABLE MICRONEEDLE PATCHES MARKET SIZE, BY COSMETIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL DISSOLVABLE MICRONEEDLE PATCHES MARKET SIZE, BY COSMETIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL DISSOLVABLE MICRONEEDLE PATCHES MARKET SIZE, BY PHARMACEUTICAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL DISSOLVABLE MICRONEEDLE PATCHES MARKET SIZE, BY PHARMACEUTICAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL DISSOLVABLE MICRONEEDLE PATCHES MARKET SIZE, BY PHARMACEUTICAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL DISSOLVABLE MICRONEEDLE PATCHES MARKET SIZE, BY PHARMACEUTICAL, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL DISSOLVABLE MICRONEEDLE PATCHES MARKET SIZE, BY ANALGESIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL DISSOLVABLE MICRONEEDLE PATCHES MARKET SIZE, BY ANALGESIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL DISSOLVABLE MICRONEEDLE PATCHES MARKET SIZE, BY ANALGESIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL DISSOLVABLE MICRONEEDLE PATCHES MARKET SIZE, BY INSULIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL DISSOLVABLE MICRONEEDLE PATCHES MARKET SIZE, BY INSULIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL DISSOLVABLE MICRONEEDLE PATCHES MARKET SIZE, BY INSULIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL DISSOLVABLE MICRONEEDLE PATCHES MARKET SIZE, BY VACCINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL DISSOLVABLE MICRONEEDLE PATCHES MARKET SIZE, BY VACCINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL DISSOLVABLE MICRONEEDLE PATCHES MARKET SIZE, BY VACCINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL DISSOLVABLE MICRONEEDLE PATCHES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL DISSOLVABLE MICRONEEDLE PATCHES MARKET SIZE, BY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL DISSOLVABLE MICRONEEDLE PATCHES MARKET SIZE, BY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL DISSOLVABLE MICRONEEDLE PATCHES MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL DISSOLVABLE MICRONEEDLE PATCHES MARKET SIZE, BY HOME HEALTHCARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL DISSOLVABLE MICRONEEDLE PATCHES MARKET SIZE, BY HOME HEALTHCARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL DISSOLVABLE MICRONEEDLE PATCHES MARKET SIZE, BY HOME HEALTHCARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL DISSOLVABLE MICRONEEDLE PATCHES MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL DISSOLVABLE MICRONEEDLE PATCHES MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL DISSOLVABLE MICRONEEDLE PATCHES MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL DISSOLVABLE MICRONEEDLE PATCHES MARKET SIZE, BY RESEARCH LABORATORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL DISSOLVABLE MICRONEEDLE PATCHES MARKET SIZE, BY RESEARCH LABORATORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL DISSOLVABLE MICRONEEDLE PATCHES MARKET SIZE, BY RESEARCH LABORATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL DISSOLVABLE MICRONEEDLE PATCHES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL DISSOLVABLE MICRONEEDLE PATCHES MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL DISSOLVABLE MICRONEEDLE PATCHES MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL DISSOLVABLE MICRONEEDLE PATCHES MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL DISSOLVABLE MICRONEEDLE PATCHES MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL DISSOLVABLE MICRONEEDLE PATCHES MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL DISSOLVABLE MICRONEEDLE PATCHES MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL DISSOLVABLE MICRONEEDLE PATCHES MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL DISSOLVABLE MICRONEEDLE PATCHES MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL DISSOLVABLE MICRONEEDLE PATCHES MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL DISSOLVABLE MICRONEEDLE PATCHES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. AMERICAS DISSOLVABLE MICRONEEDLE PATCHES MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 57. AMERICAS DISSOLVABLE MICRONEEDLE PATCHES MARKET SIZE, BY POLYMER TYPE, 2018-2032 (USD MILLION)
  • TABLE 58. AMERICAS DISSOLVABLE MICRONEEDLE PATCHES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 59. AMERICAS DISSOLVABLE MICRONEEDLE PATCHES MARKET SIZE, BY PHARMACEUTICAL, 2018-2032 (USD MILLION)
  • TABLE 60. AMERICAS DISSOLVABLE MICRONEEDLE PATCHES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 61. AMERICAS DISSOLVABLE MICRONEEDLE PATCHES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 62. NORTH AMERICA DISSOLVABLE MICRONEEDLE PATCHES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. NORTH AMERICA DISSOLVABLE MICRONEEDLE PATCHES MARKET SIZE, BY POLYMER TYPE, 2018-2032 (USD MILLION)
  • TABLE 64. NORTH AMERICA DISSOLVABLE MICRONEEDLE PATCHES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 65. NORTH AMERICA DISSOLVABLE MICRONEEDLE PATCHES MARKET SIZE, BY PHARMACEUTICAL, 2018-2032 (USD MILLION)
  • TABLE 66. NORTH AMERICA DISSOLVABLE MICRONEEDLE PATCHES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 67. NORTH AMERICA DISSOLVABLE MICRONEEDLE PATCHES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 68. LATIN AMERICA DISSOLVABLE MICRONEEDLE PATCHES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. LATIN AMERICA DISSOLVABLE MICRONEEDLE PATCHES MARKET SIZE, BY POLYMER TYPE, 2018-2032 (USD MILLION)
  • TABLE 70. LATIN AMERICA DISSOLVABLE MICRONEEDLE PATCHES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 71. LATIN AMERICA DISSOLVABLE MICRONEEDLE PATCHES MARKET SIZE, BY PHARMACEUTICAL, 2018-2032 (USD MILLION)
  • TABLE 72. LATIN AMERICA DISSOLVABLE MICRONEEDLE PATCHES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 73. LATIN AMERICA DISSOLVABLE MICRONEEDLE PATCHES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 74. EUROPE, MIDDLE EAST & AFRICA DISSOLVABLE MICRONEEDLE PATCHES MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 75. EUROPE, MIDDLE EAST & AFRICA DISSOLVABLE MICRONEEDLE PATCHES MARKET SIZE, BY POLYMER TYPE, 2018-2032 (USD MILLION)
  • TABLE 76. EUROPE, MIDDLE EAST & AFRICA DISSOLVABLE MICRONEEDLE PATCHES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 77. EUROPE, MIDDLE EAST & AFRICA DISSOLVABLE MICRONEEDLE PATCHES MARKET SIZE, BY PHARMACEUTICAL, 2018-2032 (USD MILLION)
  • TABLE 78. EUROPE, MIDDLE EAST & AFRICA DISSOLVABLE MICRONEEDLE PATCHES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 79. EUROPE, MIDDLE EAST & AFRICA DISSOLVABLE MICRONEEDLE PATCHES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 80. EUROPE DISSOLVABLE MICRONEEDLE PATCHES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. EUROPE DISSOLVABLE MICRONEEDLE PATCHES MARKET SIZE, BY POLYMER TYPE, 2018-2032 (USD MILLION)
  • TABLE 82. EUROPE DISSOLVABLE MICRONEEDLE PATCHES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 83. EUROPE DISSOLVABLE MICRONEEDLE PATCHES MARKET SIZE, BY PHARMACEUTICAL, 2018-2032 (USD MILLION)
  • TABLE 84. EUROPE DISSOLVABLE MICRONEEDLE PATCHES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 85. EUROPE DISSOLVABLE MICRONEEDLE PATCHES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 86. MIDDLE EAST DISSOLVABLE MICRONEEDLE PATCHES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. MIDDLE EAST DISSOLVABLE MICRONEEDLE PATCHES MARKET SIZE, BY POLYMER TYPE, 2018-2032 (USD MILLION)
  • TABLE 88. MIDDLE EAST DISSOLVABLE MICRONEEDLE PATCHES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 89. MIDDLE EAST DISSOLVABLE MICRONEEDLE PATCHES MARKET SIZE, BY PHARMACEUTICAL, 2018-2032 (USD MILLION)
  • TABLE 90. MIDDLE EAST DISSOLVABLE MICRONEEDLE PATCHES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 91. MIDDLE EAST DISSOLVABLE MICRONEEDLE PATCHES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 92. AFRICA DISSOLVABLE MICRONEEDLE PATCHES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. AFRICA DISSOLVABLE MICRONEEDLE PATCHES MARKET SIZE, BY POLYMER TYPE, 2018-2032 (USD MILLION)
  • TABLE 94. AFRICA DISSOLVABLE MICRONEEDLE PATCHES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 95. AFRICA DISSOLVABLE MICRONEEDLE PATCHES MARKET SIZE, BY PHARMACEUTICAL, 2018-2032 (USD MILLION)
  • TABLE 96. AFRICA DISSOLVABLE MICRONEEDLE PATCHES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 97. AFRICA DISSOLVABLE MICRONEEDLE PATCHES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 98. ASIA-PACIFIC DISSOLVABLE MICRONEEDLE PATCHES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 99. ASIA-PACIFIC DISSOLVABLE MICRONEEDLE PATCHES MARKET SIZE, BY POLYMER TYPE, 2018-2032 (USD MILLION)
  • TABLE 100. ASIA-PACIFIC DISSOLVABLE MICRONEEDLE PATCHES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 101. ASIA-PACIFIC DISSOLVABLE MICRONEEDLE PATCHES MARKET SIZE, BY PHARMACEUTICAL, 2018-2032 (USD MILLION)
  • TABLE 102. ASIA-PACIFIC DISSOLVABLE MICRONEEDLE PATCHES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 103. ASIA-PACIFIC DISSOLVABLE MICRONEEDLE PATCHES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL DISSOLVABLE MICRONEEDLE PATCHES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 105. ASEAN DISSOLVABLE MICRONEEDLE PATCHES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 106. ASEAN DISSOLVABLE MICRONEEDLE PATCHES MARKET SIZE, BY POLYMER TYPE, 2018-2032 (USD MILLION)
  • TABLE 107. ASEAN DISSOLVABLE MICRONEEDLE PATCHES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 108. ASEAN DISSOLVABLE MICRONEEDLE PATCHES MARKET SIZE, BY PHARMACEUTICAL, 2018-2032 (USD MILLION)
  • TABLE 109. ASEAN DISSOLVABLE MICRONEEDLE PATCHES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 110. ASEAN DISSOLVABLE MICRONEEDLE PATCHES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 111. GCC DISSOLVABLE MICRONEEDLE PATCHES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 112. GCC DISSOLVABLE MICRONEEDLE PATCHES MARKET SIZE, BY POLYMER TYPE, 2018-2032 (USD MILLION)
  • TABLE 113. GCC DISSOLVABLE MICRONEEDLE PATCHES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 114. GCC DISSOLVABLE MICRONEEDLE PATCHES MARKET SIZE, BY PHARMACEUTICAL, 2018-2032 (USD MILLION)
  • TABLE 115. GCC DISSOLVABLE MICRONEEDLE PATCHES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 116. GCC DISSOLVABLE MICRONEEDLE PATCHES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 117. EUROPEAN UNION DISSOLVABLE MICRONEEDLE PATCHES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 118. EUROPEAN UNION DISSOLVABLE MICRONEEDLE PATCHES MARKET SIZE, BY POLYMER TYPE, 2018-2032 (USD MILLION)
  • TABLE 119. EUROPEAN UNION DISSOLVABLE MICRONEEDLE PATCHES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 120. EUROPEAN UNION DISSOLVABLE MICRONEEDLE PATCHES MARKET SIZE, BY PHARMACEUTICAL, 2018-2032 (USD MILLION)
  • TABLE 121. EUROPEAN UNION DISSOLVABLE MICRONEEDLE PATCHES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 122. EUROPEAN UNION DISSOLVABLE MICRONEEDLE PATCHES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 123. BRICS DISSOLVABLE MICRONEEDLE PATCHES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 124. BRICS DISSOLVABLE MICRONEEDLE PATCHES MARKET SIZE, BY POLYMER TYPE, 2018-2032 (USD MILLION)
  • TABLE 125. BRICS DISSOLVABLE MICRONEEDLE PATCHES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 126. BRICS DISSOLVABLE MICRONEEDLE PATCHES MARKET SIZE, BY PHARMACEUTICAL, 2018-2032 (USD MILLION)
  • TABLE 127. BRICS DISSOLVABLE MICRONEEDLE PATCHES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 128. BRICS DISSOLVABLE MICRONEEDLE PATCHES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 129. G7 DISSOLVABLE MICRONEEDLE PATCHES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 130. G7 DISSOLVABLE MICRONEEDLE PATCHES MARKET SIZE, BY POLYMER TYPE, 2018-2032 (USD MILLION)
  • TABLE 131. G7 DISSOLVABLE MICRONEEDLE PATCHES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 132. G7 DISSOLVABLE MICRONEEDLE PATCHES MARKET SIZE, BY PHARMACEUTICAL, 2018-2032 (USD MILLION)
  • TABLE 133. G7 DISSOLVABLE MICRONEEDLE PATCHES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 134. G7 DISSOLVABLE MICRONEEDLE PATCHES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 135. NATO DISSOLVABLE MICRONEEDLE PATCHES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 136. NATO DISSOLVABLE MICRONEEDLE PATCHES MARKET SIZE, BY POLYMER TYPE, 2018-2032 (USD MILLION)
  • TABLE 137. NATO DISSOLVABLE MICRONEEDLE PATCHES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 138. NATO DISSOLVABLE MICRONEEDLE PATCHES MARKET SIZE, BY PHARMACEUTICAL, 2018-2032 (USD MILLION)
  • TABLE 139. NATO DISSOLVABLE MICRONEEDLE PATCHES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 140. NATO DISSOLVABLE MICRONEEDLE PATCHES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 141. GLOBAL DISSOLVABLE MICRONEEDLE PATCHES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 142. UNITED STATES DISSOLVABLE MICRONEEDLE PATCHES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 143. UNITED STATES DISSOLVABLE MICRONEEDLE PATCHES MARKET SIZE, BY POLYMER TYPE, 2018-2032 (USD MILLION)
  • TABLE 144. UNITED STATES DISSOLVABLE MICRONEEDLE PATCHES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 145. UNITED STATES DISSOLVABLE MICRONEEDLE PATCHES MARKET SIZE, BY PHARMACEUTICAL, 2018-2032 (USD MILLION)
  • TABLE 146. UNITED STATES DISSOLVABLE MICRONEEDLE PATCHES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 147. UNITED STATES DISSOLVABLE MICRONEEDLE PATCHES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 148. CHINA DISSOLVABLE MICRONEEDLE PATCHES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 149. CHINA DISSOLVABLE MICRONEEDLE PATCHES MARKET SIZE, BY POLYMER TYPE, 2018-2032 (USD MILLION)
  • TABLE 150. CHINA DISSOLVABLE MICRONEEDLE PATCHES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 151. CHINA DISSOLVABLE MICRONEEDLE PATCHES MARKET SIZE, BY PHARMACEUTICAL, 2018-2032 (USD MILLION)
  • TABLE 152. CHINA DISSOLVABLE MICRONEEDLE PATCHES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 153. CHINA DISSOLVABLE MICRONEEDLE PATCHES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)